Why I think these 2 ASX growth shares could keep marching upwards

Still down heavily in 2022, here are two ideas that I think could rebound.

| More on:
A young boy pushes his bicycle uphill on a rocky road. He is wearing a helmet and has his tongue hanging out as though he is making a face to show how exhausted he is.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • After recent share market volatility, I think investors can find some attractive opportunities
  • Temple & Webster is a leading e-commerce business that is growing revenue and investing
  • Volpara offers leading breast screening and risk assessment software

It has been a volatile year for some of the ASX's leading growth shares. Since the start of 2022, many names known for quickly growing revenue have seen share price declines.

I wouldn't say that every single thing that has fallen is an opportunity, but there are some that I believe have very promising futures, and the lower prices represent good buying.

Quite a few ASX growth shares have rebounded strongly over the past month. For example, the Zip Co Ltd (ASX: ZIP) share price is up 65% over the last month at the time of writing. But I'm not talking about Zip in this article.

I think the two ASX growth shares below have a promising and profitable future. Here's why.

Temple & Webster Group Ltd (ASX: TPW)

Temple & Webster is a leading e-commerce business that sells a wide array of homewares and furniture.

It offers for sale more than 200,000 products from hundreds of suppliers. Those products are sent directly to customers by suppliers, which reduces the need to hold inventory, allowing for a more extensive product range.

Temple & Webster also has its own product range and recently launched The Build, a website to sell home improvement products.

The Temple & Webster share price is currently down by 64% in 2022, which I believe makes it attractively priced. It's up 17% in the last month.

This ASX growth share grew revenue by 23% between 1 January 2022 to 30 April 2022, compared to the prior corresponding period. Revenue was up 116% compared to 2020.

The company is using its rapidly-growing revenue to invest in areas building 'key strategic moats' around the business. This includes data, personalisation, artificial intelligence, augmented reality and logistics.

It's also pursuing further organic growth opportunities, such as its private label offering, and keeping an eye out for acquisitions.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara describes itself as a global leader in the research and development of artificial intelligence for the early detection of breast cancer.

Its software provides clinicians feedback on breast density, compression, dose and quality, enabling them to offer patients personalised breast care and enhanced risk assessment.

The Volpara share price has fallen 38% since the start of 2022, but it's up 46% in the last month.

Its FY22 result displayed a number of attractive statistics. Total revenue rose 32% to NZ$26.1 million and the gross profit margin was 91%. The market share continues to grow – in FY22, 35.5% of US women had a group product applied to their images and data (up from 32% in the prior year).

The ASX growth share has also signed important deals in the last few weeks. It has announced a new research and development collaboration with Microsoft to accelerate the creation of a product that uses mammograms to identify potential cardiovascular issues. Volpara said that breast arterial calcifications were shown to be associated with cardiovascular disease outcomes.

It has also signed a deal with RadNet Inc, which includes Volpara Analytics software and Volpara Risk Pathways software. Risk Pathways will be embedded into eRAD, RadNet's electronic medical record system. The contract incorporates a volume-based model with potential upside.

I think ongoing revenue growth will help as the company benefits from operating leverage, and grows from the deals it has signed.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Microsoft, Temple & Webster Group Ltd, VOLPARA FPO NZ, and ZIPCOLTD FPO. The Motley Fool Australia has positions in and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Happy woman looking for groceries. as she watches the Coles share price and Woolworths share price on her phone
Opinions

Why I bought this ASX 200 stock instead of Woolworths

I decided to put this stock in my shopping basket over Woolies.

Read more »

A happy construction worker or miner holds a fistfull of Australian money, indicating a dividends windfall
Dividend Investing

Invest $12,000 in Woodside stock and get $5,700 in passive income

Reliable dividend shares are everywhere on the ASX. Here's how you could use that to your advantage.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Cheap Shares

1 secretly cheap ASX 200 stock I'm buying for the long run

The best performer on the index last year has had a poor start to 2024. Let's examine whether this is…

Read more »

ventilator mask
Opinions

Here's why I think the Resmed share price should be 18% higher

Just because a company's share price has gone up doesn't mean it's no longer good value.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Index investing

3 top ASX index funds to buy now

I think these index funds are well worth a look right now.

Read more »